title: Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy.
abstract: Recently published Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend limiting the use of immunosuppressive drugs in idiopathic membranous nephropathy to patients at the highest risk of kidney failure. However, recommendations are based on natural history rather than direct assessment of a restrictive treatment strategy. Here, we describe the long-term outcomes of treating a large cohort of patients with idiopathic membranous nephropathy according to a restrictive treatment policy. We analyzed data for 254 patients who visited our outpatient clinic between 1995 and 2009. All patients were treated with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers. Immunosuppressive therapy was recommended in cases of deteriorating renal function or untreatable nephrotic syndrome. Primary outcomes for the present study were renal replacement therapy and death. Secondary outcomes included adverse events during follow-up and remission of proteinuria. In total, 124 patients (49%) received immunosuppressive therapy, which predominantly consisted of cyclophosphamide combined with steroids. Ten-year cumulative incidence rates were 3% for renal replacement therapy and 10% for death. Partial remission rates were 39%, 70%, and 83% after 1, 3, and 5 years, respectively; complete remission rates were 5%, 24%, and 38% at 1, 3, and 5 years, respectively. A serious adverse event occurred in 23% of all patients. The most notable complications were infections (17%), leukopenia (18%), cardiovascular events (13%), and malignancies (8%). In conclusion, the use of a restrictive treatment strategy in this cohort of patients with idiopathic membranous nephropathy yielded favorable outcomes while limiting the number of patients exposed to toxic drugs. These results support current KDIGO guidelines.
authors.affiliation: Department of Nephrology, Radboud University Medical Centre, Nijmegen, The Netherlands, and.
authors.forename: Jan A J G
authors.initials: JA
authors.lastname: van den Brand
authors.forename: Peter R
authors.initials: PR
authors.lastname: van Dijk
authors.forename: Julia M
authors.initials: JM
authors.lastname: Hofstra
authors.forename: Jack F M
authors.initials: JF
authors.lastname: Wetzels
mesh_terms: D000328:Adult; D000368:Aged; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D015433:Glomerulonephritis, Membranous / Q000150:complications / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D011507:Proteinuria / Q000628:therapy; D012074:Remission Induction; D017582:Renal Replacement Therapy; D016896:Treatment Outcome
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007166:Immunosuppressive Agents
references.citation: N Engl J Med. 2009 Jul 2;361(1):11-21
references.pmid: 19571279
references.citation: Lancet. 2013 Mar 2;381(9868):744-51
references.pmid: 23312808
references.citation: Am J Kidney Dis. 2007 Sep;50(3):396-403
references.pmid: 17720518
references.citation: Nephrol Dial Transplant. 2010 Jun;25(6):1760-6
references.pmid: 20133280
references.citation: Nephrol Dial Transplant. 2010 Jan;25(1):129-36
references.pmid: 19666912
references.citation: Kidney Int. 2004 Sep;66(3):1199-205
references.pmid: 15327418
references.citation: J Am Soc Nephrol. 2007 Jun;18(6):1899-904
references.pmid: 17494881
references.citation: Kidney Int. 1997 Mar;51(3):901-7
references.pmid: 9067928
references.citation: Clin J Am Soc Nephrol. 2012 Jan;7(1):43-51
references.pmid: 22076873
references.citation: Clin J Am Soc Nephrol. 2011 Dec;6(12):2846-53
references.pmid: 22157712
references.citation: QJM. 1998 May;91(5):359-66
references.pmid: 9709470
references.citation: QJM. 2004 Jun;97(6):353-60
references.pmid: 15152109
references.citation: J Am Soc Nephrol. 2005 Jan;16(1):169-74
references.pmid: 15563570
references.citation: Kidney Int. 1995 Nov;48(5):1600-4
references.pmid: 8544420
references.citation: J Rheumatol. 2008 Jan;35(1):100-5
references.pmid: 17937462
references.citation: J Am Soc Nephrol. 2010 Apr;21(4):697-704
references.pmid: 20110379
references.citation: Am J Kidney Dis. 2007 Aug;50(2):248-56
references.pmid: 17660026
references.citation: Nephrol Dial Transplant. 2011 Sep;26(9):2871-7
references.pmid: 21427071
references.citation: Ann Intern Med. 1991 May 1;114(9):725-30
references.pmid: 2012353
references.citation: Medicine (Baltimore). 2010 Jul;89(4):227-235
references.pmid: 20616662
references.citation: Nephrol Dial Transplant. 2012 Jan;27(1):6-9
references.pmid: 21737514
references.citation: Nephrol Dial Transplant. 2012 Jan;27(1):235-42
references.pmid: 21558430
references.citation: Ann Rheum Dis. 2004 Oct;63(10):1307-11
references.pmid: 15130900
references.citation: J Am Soc Nephrol. 1998 Mar;9(3):444-50
references.pmid: 9513907
references.citation: Am J Kidney Dis. 2005 Dec;46(6):1012-29
references.pmid: 16310567
references.citation: Clin J Am Soc Nephrol. 2011 Jul;6(7):1591-8
references.pmid: 21685024